Amgen Q1 Results: Routine Update Amidst Structural Headwinds

What happened

Amgen reported first-quarter 2026 financial results on April 30, a routine update that provided no unexpected surprises but also no material positive catalysts. The company continues to operate under the pressure of accelerating ENBREL price erosion (38% net price decline in Q3 2025), impending IRA impacts on Otezla, and imminent biosimilar competition for Prolia/XGEVA, as detailed in the latest filings. Newer products like Repatha, Tezspire, and Horizon assets (Tepezza, Uplizna) are growing but likely still insufficient to fully offset legacy erosion, consistent with the base-case scenario of ~3-4% revenue growth. The market narrative continues to ascribe obesity optionality to MariTide, yet Phase 3 data remains years away, while leverage (net debt/EBITDA ~4.1x) and an unresolved IRS tax dispute provide little cushion. This quarter’s results likely confirm that the fundamental trajectory remains on the lower end of expectations, reinforcing the cautious outlook from the prior analysis.

Implication

The first-quarter report provides no catalyst to justify the current ~23.7x P/E premium, as the core business faces accelerating legacy erosion from IRA, 340B, and biosimilars while obesity optionality remains years away. Investors should use any strength to reduce positions; a pullback to the attractive entry zone (~$295) would offer a more favorable risk-reward. Key triggers to watch: ENBREL sales trajectory, Horizon asset growth consistency, and any early readouts from MariTide Phase 3 (MARITIME program).

Thesis delta

The Q1 update does not materially alter the investment thesis; the fundamental picture remains consistent with the previous assessment of structural headwinds and obesity optionality that is still distant. The lack of any positive surprise reinforces the cautious stance, as the stock’s valuation already embeds substantial growth expectations that are increasingly challenged by policy and competitive pressures. No revision to the base-case scenario is warranted; the sell rating with a trim above $370 and attractive entry near $295 remains appropriate.